Total: $76.5M | ||||
Company |
Type Of Financing |
Number Of Shares, Units Or Warrants |
Amount Raised (M) |
Investors; Placement Agents; Details |
| | ||||
Alteon Inc. |
Private placement of common stock |
2.3S |
$7.7 |
Alteon raised about $7.7M with the sale of 2.3M shares at $3.50 per share to institutional investors (3/26) |
|
|
|||
Biopure Corp. |
Private placement of common stock and warrants |
5.5S and W |
$13.4 |
Biopure raised $13.4M selling 5.5M shares at $2.42 apiece; for each five shares purchased, investors also received one warrant to purchase one share (3/25) |
|
|
|||
Boston Life |
Private placement of common stock |
10S |
$10 |
Boston Life Sciences raised $10M in the private placement with a small group of individual investors (3/13) |
|
|
|||
Cypress |
Private placement of shares and warrants |
4S and W for 1S |
$10.3 |
Cypress raised $10.3M in the private placement (3/27) |
|
||||
Dyax Corp. |
Private placement of common stock |
4.7S |
$8.8 |
Dyax raised $8.8M through the sale of about 4.7M shares to selected institutional and other accredited investors; Lancet Capital and Federated Kaufman Fund led the offering; Pacific Growth Equities LLC acted as exclusive placement agent (3/14) |
|
||||
Genta Inc. |
Credit facility |
N/A |
-- |
Genta received a $40M line of credit from Aventis related to the development of Genasense (3/17) |
|
|
|||
Orphan |
Revolving line of credit |
N/A |
-- |
Orphan Medical obtained a revolving line of credit with Silicon Valley Bank; the line of credit provides the lesser of $3.5M or 75% of qualifying assets and carries an interest rate on borrowings at the prime rate plus 2% (3/31) |
|
||||
Palatin Technologies |
Private placement of common stock |
13.4S |
$19 |
Palatin raised $19M through the sale of 13.4M shares; investors were ProQuest LLC, Federated Kaufmann Funds, Albert Fried & Co., Lurie Investments, Biotechnology Value Fund LP and Legg Mason Wood Walker Inc. (3/31) |
|
||||
Pharmos Corp. |
Private placement of common stock and warrants |
N/A |
$4.3 |
Pharmos raised $4.3M in the private placement with a group of institutional investors (3/5) |
|
|
|||
Protein |
Private placement of preferred stock |
0.03S |
$3 |
Protein Polymer raised about $3M through the sale of 30,050 shares of Series I preferred stock to a small group of institutional and accredited investors (3/27) |
|
||||
|
| ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
N/A = Not available, applicable or reported. | ||||
AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange | ||||
